Obesity Drugs Changing the Treatment Landscape

1 Min Read

 

 

The future of treatment in obesity is poised to shift as the FDA relents in its harsh stance against obesity drugs, now that the is reconsidering approval for Vivus’ Qnexa. A varied array of approaches and technologies are now used in the clinical management of obesity, spanning surgery with or without devices, devices without surgery and drugs. Restrictive devices (e.g., Lap-Band) and appetite suppressants currently represent the largest aggregate in the market, but with new drug approvals and the continued evolution of device-based obesity treatments, the balance of the market will change.

Below is illustrated the 2009 and forecast 2019 global market for obesity treatments categorized by type.  Device sales and new drugs will begin to gain a greater share of the market.

Source: MedMarket Diligence, LLC; Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2009-2019.”
      

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version